Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report
Carbapenem-resistant <i>Acinetobacter baumannii</i> (CR<i>Ab</i>) causes severe infections and poses significant treatment challenges. Sulbactam-durlobactam (SUL-DUR) is a novel antibiotic, but its use in children and infants has not been reported. We reported the first case of an infant with acute leukemia successfully treated with SUL-DUR for CR<i>Ab</i> sepsis with cutaneous involvement.
Authors
- Xue Tang (ORCID: https://orcid.org/0000-0002-3983-979X)
- C. Fu (ORCID: https://orcid.org/0000-0002-2047-4778)
- Xia Guo (ORCID: https://orcid.org/0000-0003-0589-6638)
- Ju Gao (ORCID: https://orcid.org/0000-0001-5893-9406)
- Liang Huang (ORCID: https://orcid.org/0000-0001-7937-8150)
- Rong Hua Yang
Institutions
- Sichuan University (CN)
- West China Second University Hospital of Sichuan University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-04
- DOI
- https://doi.org/10.3389/fphar.2025.1633982
- Citations
- 4
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 2.36